ICER president Steven Pearson at JPM23 (Adrien Villez for Endpoints News)

At $2M per shot, ICER says two new sick­le cell gene ther­a­pies could be cost-ef­fec­tive

Gene ther­a­pies ap­proved by the FDA have so far brought with them eye-pop­ping prices of $2 mil­lion or more be­cause of the ex­tra­or­di­nary sav­ings, some­times over a life­time, that can oc­cur if the ther­a­pies prove safe, ef­fec­tive and durable.

In the case of the in­com­ing sick­le cell dis­ease gene ther­a­pies from Ver­tex Phar­ma­ceu­ti­cals and CRISPR Ther­a­peu­tics, known as ex­agam­glo­gene au­totem­cel or exa-cel, and blue­bird bio’s lovotibeglo­gene au­totem­cel or lo­vo-cel, ICER said that for a price of about $2 mil­lion per po­ten­tial shot, the ther­a­pies could be cost ef­fec­tive un­der some sce­nar­ios al­though “these gene ther­a­pies have an in­cre­men­tal cost ef­fec­tive­ness that is above com­mon­ly cit­ed thresh­olds from the health care sys­tem per­spec­tive.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.